Table 2.

Risk factors of CIPN by neurotoxic drug classification

Agent	Risk factors
Cisplatin	Prior or concomitant administration of taxanes, single and cumulative dose level, pre-existing peripheral neuropathy
Oxaliplatin
Acute form	Cold, duration of infusion (2-hour vs 4- or 6-hour infusion)
Chronic form	Single and cumulative dose level, severity of the acute form of neurotoxicity, time of infusion, pre-existing peripheral neuropathy, treatment duration
Paclitaxel	Single and cumulative dose level, prior or concomitant administration of platinum compounds, pre-existing peripheral neuropathy, duration of infusion (1- to 3-hour vs 24-hour infusion)
Docetaxel	Single and cumulative dose level, prior or concomitant administration of platinum compounds, pre-existing peripheral neuropathy
Epothilones	Single and cumulative dose level, prior or concomitant administration of platinum compounds, pre-existing peripheral neuropathy
Bortezomib	Single and cumulative dose level, pre-existing peripheral neuropathy
Thalidomide	Same as bortezomib
Lenalidomide	Same as bortezomib
Pomalodomide	Same as bortezomib
Vincristine	Single and cumulative dose level, treatment duration
Suramin	Single and cumulative dose level

Abbreviation: CIPN, chemotherapy-induced peripheral neuropathy.